Riccardo Braglia, Helsinn Group’s Vice Chairman and CEO, Managing Director and Member of Helsinn Holding’s Board of Directors, Switzerland and Executive Committee for Helsinn Group’s strategic management, has a wealth of over 30 years of international experience in the pharmaceutical industry. Mr. Braglia heads the family-run, privately owned pharmaceutical company, the Helsinn Group, founded in 1976, with a worldwide presence and focus on cancer therapeutics and supportive care. Mr. Braglia is a Board Member of Helsinn Healthcare, Switzerland, Helsinn Advanced Synthesis, Switzerland, Helsinn Birex Pharmaceuticals, Ireland and Chairman of Helsinn Therapeutics, USA. He is also Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco and Chairman of the Helsinn Investment Fund, Luxembourg. Mr. Braglia serves as a Board Member of two portfolio companies of the Helsinn Investment Fund, QuantumDx Group Limited, UK and GreenBone Ortho S.R.L., Italy. He is also Co-founder and Board Member of Lyfebulb, USA, and a Board Member of Thorne Research, Greenwich CT/USA, Wellness-Fx and Health Elements.com, all US companies. Mr. Braglia is a member of the Board of the Conquer Cancer Foundation, USA. Mr. Braglia is also active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures. Riccardo Braglia holds a degree in Business Economics with a specialization in Business Industrial Management from the Luigi Bocconi University of Milan, Italy.